Ask AI
ProCE Banner Activity

Missed Opportunities in Heart Failure Care: Supporting Early Diagnosis With Cardiac Biomarkers and Maximizing Treatment Potential With SGLT2 Inhibitors

Slideset

Expert-curated slides on the importance of diagnosing heart failure early, including current evidence and strategies for using cardiac biomarkers, and how to maximize guideline-directed medical therapy with SGLT2 inhibitors across the ejection fraction spectrum. 

Released: October 29, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Faculty Disclosure

Primary Author

Javed Butler, MD, MPH, MBA: consultant/advisor/speaker: Abbott, Adaptyx, American Regent, Amgen, AskBio, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Vifor, CVRx, Cytokinetics, Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Innolife, Impulse Dynamics, Imbria, Intellia, Inventiva, Levator, Lexicon, Lilly, MannKind, Medtronics, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, Rycarma, Salient, Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultromic, Vera, Zoll.

Ty J. Gluckman, MD, MHA, has no relevant financial relationships to disclose.